Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy

TGF-β suppresses type 2 immunity to cancer

(2020) Ming Liu et al.   NATURE

Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

(2020) Shun Li et al.   NATURE

Driving CAR T cell translation forward

(2019) Liora Schultz et al.   Science Translational Medicine

Tumor-derived TGF-β inhibits mitochondrial respiration to suppress IFN-γ production by human CD4+ T cells

(2019) Sarah Dimeloe et al.   Science Signaling

PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges

(2019) Eileen McGowan et al.   BIOMEDICINE & PHARMACOTHERAPY

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

Mechanisms of Resistance to PD-1 and PD-L1 Blockade

(2018) Theodore S. Nowicki et al.   CANCER JOURNAL

TGF-β Inhibition and Immunotherapy: Checkmate

(2018) Karuna Ganesh et al.   IMMUNITY

Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+ T cell response in esophageal squamous cell carcinoma

(2018) Xinfeng Chen et al.   INTERNATIONAL JOURNAL OF CANCER

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

(2018) Rajani Ravi et al.   Nature Communications

CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction

(2018) Natnaree Siriwon et al.   Cancer Immunology Research

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

(2018) Yao Wang et al.   OncoImmunology

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

(2018) Rikke B. Holmgaard et al.   Journal for ImmunoTherapy of Cancer

TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer

(2018) Daniel R Principe et al.   MOLECULAR CANCER THERAPEUTICS

Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas

(2017) Guoying Zhou et al.   GASTROENTEROLOGY

Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers

(2017) Chengcheng Zhang et al.   MOLECULAR THERAPY

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?

(2017) Sylvain Simon et al.   OncoImmunology

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

(2017) Nabil Ahmed et al.   JAMA Oncology

Coinhibitory Pathways in Immunotherapy for Cancer

(2016) Susanne H. Baumeister et al.   Annual Review of Immunology

Driving CAR T-cells forward

(2016) Hollie J. Jackson et al.   Nature Reviews Clinical Oncology

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

(2016) Ruea-Yea Huang et al.   OncoImmunology

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

(2014) ALLEN COHN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

TGF- : Guardian of T Cell Function

(2013) S. A. Oh et al.   JOURNAL OF IMMUNOLOGY

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

TGFβ signalling in context

(2012) Joan Massagué   NATURE REVIEWS MOLECULAR CELL BIOLOGY

T-Cell Engineering for Cancer Immunotherapy

(2009) Michel Sadelain   CANCER JOURNAL

Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression

(2009) Ethan M. Shevach   IMMUNITY

TGF-β: A Master of All T Cell Trades

(2008) Ming O. Li et al.   CELL